Detalles de la búsqueda
1.
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
N Engl J Med
; 377(24): 2349-2362, 2017 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29236639
2.
Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
Vaccine
; 41(17): 2729-2733, 2023 04 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37024411
3.
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Lancet Infect Dis
; 23(12): 1370-1382, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37579773
4.
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Lancet Infect Dis
; 23(1): 103-116, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36087588
5.
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Vaccine
; 40(2): 351-358, 2022 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34961633
6.
Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Vaccine
; 40(12): 1872-1878, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35164991
7.
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Vaccine
; 39(32): 4545-4554, 2021 07 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34215452
8.
Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
Postgrad Med
; 132(2): 184-191, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32124678
9.
Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.
Infect Dis Ther
; 9(3): 625-639, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32681472
10.
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.
Infect Dis Ther
; 9(3): 641-656, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700260
11.
Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence.
Hum Vaccin Immunother
; 15(9): 2205-2216, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30779683
12.
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vaccine
; 37(12): 1710-1719, 2019 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30770221
13.
Modeling excess zeroes in an integrated analysis of vaccine safety.
Hum Vaccin Immunother
; 14(6): 1530-1533, 2018 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29393713
14.
Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
Vaccine
; 36(28): 4004-4013, 2018 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29861182
15.
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
Expert Rev Vaccines
; 17(6): 461-477, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29883226
16.
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 17(1): 58-67, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27745812
17.
A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.
Vaccine
; 34(12): 1465-71, 2016 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26845739
18.
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.
J Pediatric Infect Dis Soc
; 5(2): 180-7, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26803328
19.
Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
J Pediatric Infect Dis Soc
; 5(2): 152-60, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26407272
20.
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 12(8): 597-607, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22569484
Resultados
1 -
20
de 20
1
Próxima >
>>